

Media Release – For Immediate Distribution

[InSphero AG Secures CHF 20 Million Series C Financing](#)

Leading 3D cell culture company gains new long-term investor to fuel expansion of global operations and product portfolio

Schlieren, Switzerland – July 8, 2015 – [InSphero AG](#), the world’s leading developer of easy-to-use solutions for organotypic 3D cell culture models and body-on-a-chip systems, has secured CHF 20 million in financing from the family investment office of a globally active entrepreneur represented through HP WILD HOLDING AG based in Zug, Switzerland. InSphero is using the Series C financing round to rapidly expand its global footprint, broaden its portfolio of novel 3D microtissues and contract research services for 3D drug safety and efficacy testing, and develop new products and applications based on its proven technology.

Since its commercial launch in 2010, the company has experienced strong year-over-year sales growth marked by the rapid adoption of its [3D InSight™ microtissues and services](#) by leading pharmaceutical, chemical and cosmetics companies. Since last year, large pharma organizations have begun converting from conventional assays to InSphero’s 3D microtissues.

Dr. Jan Lichtenberg, CEO and co-founder of InSphero, says that the investment round enables InSphero to leverage the successful customer implementations, robust validation data, and growing scientific evidence to become the gold standard in the field of 3D cell-based assays.

“This investment is an affirmation of InSphero’s valuable, more predictive liver, islet and tumor model systems for use throughout the drug development process,” said Lichtenberg. “The family office behind HP WILD HOLDING AG brings to InSphero long-term perspective as well as decades of experience building global brands and driving operational excellence. Their financial commitment is also strengthened by an established international network that will help us better serve growing global demand for microtissues and services, particularly in North America and Asia.”

The proceeds of the financing round will be invested to expand InSphero’s North American scientific staff and operations into a state-of-the-art bio-production facility; increase the variety of model systems available to customers across different industries; and to develop new products including InSphero’s Body-on-a-Chip technology and personalized-medicine kits to maturity.

InSphero’s pipeline includes 3D liver, skin, heart, brain and tumor models developed for toxicity testing and disease modeling, as well as next-generation 3D cell culture platforms.

For more information about InSphero, visit www.insphero.com.

###

InSphero contacts

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
randy.strube@insphero.com



InSphero AG
Wagistrasse 27
CH-8952 Schlieren
Switzerland
Tel: +41 (44) 515049-0
Fax: +41 (44) 515049-1
www.insphero.com

Dr. Jan Lichtenberg
CEO and Co-Founder
Phone +41 44 5150490
jan.lichtenberg@insphero.com

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in [peer-reviewed journals](#), through collaborative projects such as [EU Body on a Chip](#) and [HeCaToS](#), and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international [awards](#).

Follow us on [Twitter](#) and www.insphero.com.